Anixa Biosciences receives notice of allowance for new patent from USPTO

Anixa Biosciences (ANIX) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a new patent related to the company’s innovative breast cancer vaccine technology. The patent along with others related to this technology, has been exclusively licensed to Anixa Biosciences, by Cleveland Clinic. The patent will expand the scope of immunogenic compositions utilized in Anixa’s breast cancer vaccine. This newly allowed patent covers methods of immunizing patients against breast cancer by administering an immunogenic composition containing the human alpha-lactalbumin protein, a protein typically found in breast tissue during lactation but also expressed in certain breast cancers, making it an attractive target for immunoprevention strategies.